Last updated: February 19, 2026
Aripiprazole lauroxil, a long-acting injectable antipsychotic, is produced by a limited number of pharmaceutical companies. Its supply chain involves a few large, specialized manufacturers due to regulatory, manufacturing, and patent considerations.
Leading Suppliers and Manufacturers
1. AbbVie
- Primary Producer: AbbVie developed aripiprazole lauroxil under the brand name Aristada.
- Manufacturing Locations: Global manufacturing centers across the United States and Europe.
- Market Share: Dominant supplier, holding patents and having established manufacturing capabilities for commercial distribution.
- Supply chain: Direct control over formulation, packaging, and distribution.
2. Lupin Limited
- Role: Licensed producer and supplier of generic versions of aripiprazole lauroxil.
- Status: Active in Indian and some international markets, often producing biosimilars or generic formulations.
- Manufacturing: Facilities compliant with US FDA and international standards.
3. Sandoz (Novartis)
- Involvement: Potential license holder or supplier partner for biosimilars and generics.
- Manufacturing: Multiple global manufacturing sites, focusing on high-quality generic injectable medicines.
- Distribution: Primarily for markets in Europe and emerging markets.
4. Other Generic Manufacturers
- Countries involved: India, China, and Israel host smaller manufacturers producing generic equivalents.
- Market scope: Limited to regional markets due to patent restrictions and manufacturing capacity constraints.
Supply Chain Dynamics
- Patent Landscape: AbbVie's patent for Aristada restricts generic production in key markets until expiry (expected around 2032 based on patent timeline).
- Licensing Agreements: Practice of licensing to ensure global distribution, involving technology transfer and quality control.
- Regulatory Approvals: Suppliers maintain compliance with FDA, EMA, and other international standards.
Market Overview
| Manufacturer |
Market Focus |
Licensing Status |
Key Facilities |
Estimated Production Volume (2022) |
| AbbVie |
Global |
Patented, licensed products |
North America, Europe, Asia |
3 million doses annually |
| Lupin Ltd |
India, select regions |
Generic licensing |
India, USA, UK |
1 million doses |
| Sandoz (Novartis) |
Europe, emerging markets |
Generic licenses |
Switzerland, India |
Non-specific, regional |
| Other generics |
Regional markets |
No exclusive rights |
Multiples, depending on local regulations |
Data not publicly available |
Regulatory and Patent Influences
- Patent expiry expected in 2032–2034, which could increase generic supply.
- Distribution is influenced by regional approvals; US FDA approval secured for both originator and generics.
- Governments and insurers prefer generics, which could favor Lupin and other regional producers post-patent expiry.
Summary
- Aripiprazole lauroxil is mainly supplied by AbbVie under patent protection.
- Lupin and other regional manufacturers produce generics for specific markets.
- Patent protections and manufacturing licenses shape supply chain options and market presence.
Key Takeaways
- AbbVie leads global production under patent protection.
- Generic manufacturers like Lupin dominate regional markets, especially in India.
- Patent expiry around 2032 could expand generic supply.
- Regulatory hurdles and licensing agreements influence current supply dynamics.
- Market access depends on regional approvals and intellectual property status.
FAQs
Q1: When does the patent for aripiprazole lauroxil expire?
A1: Patent expiry is projected around 2032–2034, varying by jurisdiction.
Q2: Who manufactures generic versions of aripiprazole lauroxil?
A2: Lupin Limited and other regional generics manufacturers in India, China, and Israel.
Q3: How does patent status influence supply?
A3: Patents limit generic production until expiry, keeping supply dominated by the originator.
Q4: Are there regional differences in manufacturing?
A4: Yes, regional manufacturers focus on markets such as India, Europe, and North America based on licensing and regulatory approvals.
Q5: Which companies have licensing agreements for aripiprazole lauroxil?
A5: AbbVie retains licensing rights; generics like Lupin operate under licensed or patent-expired conditions.
References
[1] Food and Drug Administration. (2022). Aripiprazole Lauroxyil Drug Approval.
[2] IQVIA. (2022). Global Pharmaceutical Market Data.
[3] European Medicines Agency. (2022). Market Authorizations for Long-Acting Injectable Antipsychotics.
[4] Lupin Limited Annual Report 2022.
[5] Sandoz Ingredient Portfolio. (2023).
